In addition to chemotherapy, RRM2 inhibition may augment the activity of immunotherapies such as immune checkpoint inhibitors or tyrosine kinase inhibitors, as RRM2 overexpression is linked to immune escape and evasion in HCC (Mao et al. 2022; Qin et al. 2023). This evidence concerns the gene RRM2 and hepatocellular carcinoma.